Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Perspective Therapeutics (AMEX: CATX) and maintained a price target of $11 for the stock. No additional financial figures or strategic changes were mentioned in the article.